GET DAILY SIGNALSMerck (MRK) vs Novartis (NVS): Weighing Patent Risks Against Diversified Growth
Key Takeaways
- Merck & Co. (MRK) is managing a looming patent cliff for its flagship cancer drug Keytruda while accelerating new product launches and disciplined acquisitions.
- Novartis (NVS) is absorbing generic competition for Entresto while relying on faster-growing brands such as Kisqali, Kesimpta, and Pluvicto.
- Both companies beat earnings per share (EPS) estimates in their most recent quarters, but each faced top-line or forward-guidance concerns tied to product erosion.
- Relative performance differs sharply: Novartis shares have posted strong gains over the past year, while Merck's recent momentum has been choppier amid M&A headlines.
- Diverging growth drivers—oncology scale at Merck versus a diversified specialty portfolio at Novartis—define the key trade-off for investors.
Introduction
Merck & Co. and Novartis AG stand out as two of the largest pharmaceutical companies globally, yet they offer distinct profiles for investors comparing their positions in today's market. Merck operates as a U.S.-based leader with heavy concentration in oncology via its Keytruda franchise, whereas Novartis functions as a Swiss diversified player across oncology, immunology, neuroscience, and cardiovascular-renal-metabolic areas. This comparison matters for those assessing growth durability against patent risks, as well as for tracking relative performance in large-cap healthcare. I also checked this using Tickeron’s AI Screener to see how the stocks line up against peers in the sector.
Merck Overview and Recent Performance
MRK is a diversified healthcare company anchored by Keytruda, which accounts for more than half of its pharmaceutical sales. In the latest quarter, Merck delivered adjusted EPS that slightly topped estimates, with revenue up about 5% year over year, driven by Keytruda and oncology partnerships. That said, forward guidance came in below consensus, which tempered recent sentiment.
The main story centers on preparing for Keytruda's expected loss of exclusivity in 2028. Merck has pursued targeted acquisitions, including a $9.2 billion deal for Cidara Therapeutics and an earlier roughly $10 billion transaction for Verona Pharma. Newer contributors like Winrevair for pulmonary arterial hypertension and the Capvaxive pneumococcal vaccine have shown solid early traction. On the downside, Gardasil sales dropped notably due to weaker demand in China, and Merck walked away from talks to acquire Revolution Medicines over valuation differences, reflecting a disciplined approach. From what I see, these moves highlight a focus on measured expansion beyond oncology.
Novartis Overview and Recent Performance
NVS spans four primary areas: cardiovascular-renal-metabolic, immunology, neuroscience, and oncology. Its most recent results showed core EPS beating estimates, though revenue landed modestly below forecasts and remained roughly flat on a constant-currency basis. The key pressure came from generic competition on Entresto in the U.S. and erosion of Promacta.
Novartis has countered with momentum in newer products. Kisqali and Pluvicto delivered double-digit growth, Kesimpta advanced, and Cosentyx continued expanding across markets. The company has also taken steps to limit U.S. tariff exposure through voluntary pricing and expanded domestic production. Pipeline updates have been mixed, with two late-stage candidates missing targets while remibrutinib, or Rhapsido, produced positive multiple sclerosis data. Shares have risen solidly over the past year, leaving analysts with a neutral-to-cautious stance on valuation. One thing that stands out is how the diversified base helps cushion single-product setbacks.
Head-to-Head Comparison
The clearest distinction lies in concentration risk. Merck remains closely linked to Keytruda and its oncology lineup, which provides substantial scale but heightens exposure to the 2028 patent cliff. Novartis spreads revenue across several franchises, lowering dependence on any one asset yet requiring steady new launches to replace older products like Entresto.
Growth paths also differ. Merck emphasizes bolt-on deals, vaccines, and cardio-pulmonary assets to broaden beyond oncology. Novartis prioritizes organic growth in Kisqali, Pluvicto, Kesimpta, and Cosentyx alongside selective acquisitions. Risk factors include China-related vaccine softness and integration for Merck, versus generic pressure and pipeline variability for Novartis. On performance, Novartis has achieved stronger trailing returns, while Merck has shown more volatility around deal activity and guidance. I’m watching this closely as market sentiment reflects these differences, with some raised price targets for Merck alongside a Hold consensus for Novartis.
Exploring AI Trading Strategies
For investors looking at a stock comparison like this, Tickeron's AI Trading Bots provide a way to examine how systematic approaches are positioned across names such as MRK and NVS. The platform features numerous bots with varying styles, timeframes, and performance metrics, allowing users to match strategies to their own goals. In my view, reviewing these options helps clarify whether algorithmic signals align with the observed fundamentals and relative momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NVS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for NVS turned positive on September 24, 2026. Looking at past instances where NVS's MACD turned positive, the stock continued to rise in 30 of 45 cases over the following month. The odds of a continued upward trend are 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on NVS as a result. In 42 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 52%.
NVS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in 183 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 162 of 318 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for NVS moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.
NVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.043) is normal, around the industry mean (-3.196). P/E Ratio (23.078) is within average values for comparable stocks, (21.213). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (5.738). NVS has a moderately high Dividend Yield (0.123) as compared to the industry average of (0.041). P/S Ratio (4.715) is also within normal values, averaging (4.033).
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating fairly steady price growth. NVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of health care and nutritional products
Industry PharmaceuticalsMajor
Advertisement